Search results for " growth"

showing 10 items of 4263 documents

Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflamma…

2013

Maria D Pinazo-Durán,1,* Carmen Galbis-Estrada,1,* Sheila Pons-Vázquez,1 Jorge Cantú-Dibildox,2 Carla Marco-Ramírez,1 Javier Benítez-del-Castillo21Ophthalmic Research Unit Santiago Grisolia, Department of Surgery/Ophthalmology, Faculty of Medicine, University of Valencia, Valencia, Spain; 2Department of Ophthalmology, Hospital of Jerez, Jerez de la Frontera, Spain*These authors contributed equally to this workBackground: Women, and those older than 65 years of age, are particularly susceptible to dry eye disorders (DEDs). Inflammation is clearly involved in the pathogenesis of DEDs, and there is mounting evidence on the antioxidant and …

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyessential polyunsaturated fatty acidsInterleukin-1betaInflammationnutraceuticsGastroenterologyAntioxidantsPathogenesischemistry.chemical_compoundRisk FactorsInternal medicineFatty Acids Omega-3HumansMedicineProspective StudiesInterleukin 6Prospective cohort studyAgedOriginal ResearchAged 80 and overchemistry.chemical_classificationbiologyInterleukin-6business.industryagingtearsInterleukinGeneral MedicineMiddle AgedcytokinesInterleukin-10Vascular endothelial growth factorchemistryClinical Interventions in AgingDietary SupplementsImmunologybiology.proteinTearsDry Eye SyndromesFemalewomenInflammation MediatorsGeriatrics and Gerontologymedicine.symptombusinessPolyunsaturated fatty acidClinical Interventions in Aging
researchProduct

Aqueous Humor Levels of Vascular Endothelial Growth Factor in Retinitis Pigmentosa

2008

PURPOSE To determine the level of vascular endothelial growth factor A (VEGF-A) in aqueous humors of patients with retinitis pigmentosa (RP). METHODS A prospective, comparative control study. Aqueous humor was collected from 16 eyes of 16 patients with RP. The level of VEGF-A was determined with a commercially available enzyme-linked immunosorbent assay kit. The control group comprised 16 aqueous samples from 16 patients about to undergo cataract surgery and without any other ocular or systemic diseases. RESULTS The concentration of VEGF-A in aqueous humor was markedly lower in patients with RP than in control subjects (Mann-Whitney U test, P < 0.001). The level of VEGF-A was 94.9 +/- 99.8 …

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentEye diseaseEnzyme-Linked Immunosorbent AssayAqueous humorAqueous Humorchemistry.chemical_compoundOphthalmologyRetinitis pigmentosaHumansMedicineProspective StudiesAgedbusiness.industryMiddle AgedCataract surgerymedicine.diseaseControl subjectseye diseasesVascular endothelial growth factorVascular endothelial growth factor AchemistryFemalesense organsbusinessRetinitis PigmentosaRetinopathyInvestigative Opthalmology &amp; Visual Science
researchProduct

Elevated protein carbonyl and HIF-1α levels in eyes with proliferative diabetic retinopathy.

2013

Purpose: To evaluate the role of protein carbonyls and hypoxia inducible factor-1a (HIF-1a) in diabetic eyes with proliferative diabetic retinopathy (PDR). Methods: Prospective consecutive controlled observational study was performed. Vitreous samples were collected at the start of the 3-ppp vitrectomy. Protein carbonylation analysis was performed by Western blotting with antibody against 2,4-Dinitrophenol (anti-DNP), following derivatization of protein carbonyls with 2,4 Dinitrophenylhydrazine (DNHP). Protein carbonylation was quantified by scanning densitometry analysis and relativized to the total amount of protein into the ponceau staining of membranes. Vitreous HIF-1 a was determined w…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentProtein CarbonylationBlotting WesternVitrectomyEnzyme-Linked Immunosorbent Assaymedicine.disease_causePathogenesisProtein Carbonylationchemistry.chemical_compoundOphthalmologyVitrectomymedicineHumansProspective StudiesMacular holeAgedGlycated HemoglobinDiabetic Retinopathybusiness.industryRetinal detachmentGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseHypoxia-Inducible Factor 1 alpha Subuniteye diseasesSurgeryVascular endothelial growth factorVitreous BodyOphthalmologyOxidative StressDiabetes Mellitus Type 1chemistryDiabetes Mellitus Type 2Femalesense organsbusinessOxidative stressActa ophthalmologica
researchProduct

Impact of Heavy Polypropylene Mesh and Composite Light Polypropylene and Polyglactin 910 on the Inflammatory Response

2010

The aim of the study was to analyze the acute inflammatory response after implantation of a heavyweight mesh of polypropylene (PP) compared with a composite mesh of light PP and polyglactin 910 (PG) in patients undergoing inguinal hernioplasty. A total of 30 male patients with inguinal hernia were included in the study and divided into 2 groups (PP and PP-PG) according to the mesh used. Changes of leukocytes, cytokines, growth factors, and acute phase proteins were evaluated in the sera. Leukocytes and acute phase proteins were significantly increased postoperatively in both groups, and the values were slightly higher in the PP group. Cytokine levels were significantly increased postoperat…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtymedicine.medical_treatmentInflammatory responseUrologyBiocompatible MaterialsHernia InguinalPolypropylenesProinflammatory cytokinechemistry.chemical_compoundTransforming Growth Factor betaHumansMedicineHerniaPolyglactin 910AgedInflammationPolypropyleneInterleukin-6business.industryPolyglactin 910Acute-phase proteinMiddle AgedSurgical Meshmedicine.diseaseSurgeryFibroblast Growth FactorsInterleukin 1 Receptor Antagonist ProteinInguinal herniaC-Reactive ProteinCytokinechemistrySurgerybusinessSurgical Innovation
researchProduct

Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers

2000

Abstract To evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. Drugs were given as a single dose at 10:00 h for a period of 4 weeks each. Between days 21 and 28 of each treatment period, sleep EEG was registered for four consecutive nights from 23:00 to 07:00 h. During the last night, hormonal profiles for prolactin, growth hormone (GH), cortisol, corticotropin (ACTH), luteinizing hormone (LH), testosterone and melatonin w…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismSerotonin reuptake inhibitorPlaceboPlacebosMelatoninEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansBiological PsychiatryMelatoninCross-Over StudiesHuman Growth HormoneEndocrine and Autonomic SystemsElectroencephalographyLuteinizing HormoneParoxetineHormonesProlactinCircadian RhythmProlactinParoxetinePsychiatry and Mental healthEndocrinologySleep onsetReuptake inhibitorPsychologyLuteinizing hormoneSelective Serotonin Reuptake Inhibitorshormones hormone substitutes and hormone antagonistsmedicine.drugPsychoneuroendocrinology
researchProduct

Neuroendocrine response to antipsychotics: effects of drug type and gender

1999

Abstract Background: To study the influences of drug type and gender on the neuroendocrine response to neuroleptic treatment, we compared the endocrine actions of two neuroleptics with different receptor affinity profiles—a substituted benzamide, amisulpride, a selective D 2 -like dopamine antagonist; and a thioxanthene, flupenthixol, a mixed D 1 /D 2 -like antagonist also blocking serotonin, H 1 , and D 1 receptors—on anterior pituitary hormone secretion in schizophrenic patients (DSM-III-R). Methods: Blood was withdrawn at 15-min intervals to assess basal secretion of prolactin, growth hormone (GH), and thyroid-stimulating hormone (TSH). Four hundred micrograms of thyrotropin-releasing ho…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesThyrotropinThyrotropin-releasing hormoneFlupenthixolPharmacologySex FactorsDouble-Blind MethodAnterior pituitaryThyroid-stimulating hormoneInternal medicinemedicineHumansAmisulprideBiological PsychiatryHuman Growth Hormonebusiness.industryDopamine antagonistNeurosecretory SystemsProlactinProlactinFlupenthixolmedicine.anatomical_structureEndocrinologySchizophreniaFemaleSchizophrenic PsychologyAmisulprideSulpiridebusinesshormones hormone substitutes and hormone antagonistsAntipsychotic Agentsmedicine.drugHormoneBiological Psychiatry
researchProduct

Insulin-like growth factor 1 and pressure load in hypertensive patients

1996

To verify the effect of a pressure load on the production of Insulin-like Growth Factor 1 (IGF1) in essential hypertensives, we studied 15 patients and 8 normotensive controls before and during orthostatism. Upright standing was characterized both in normals and in hypertensives by significant higher rate-pressure product [RPP = systolic blood pressure (mm Hg) x heart rate (beats/min)]. Proportional increases of RPP were significantly related to IGF1 values at the end of orthostatism and to proportional increases of IGF1 in hypertensive group but not in normotensive one. Our results confirm that IGF1 plasma levels in hypertensive patients are related to pressure load.

AdultMaleendocrine systemmedicine.medical_specialtymedicine.medical_treatmentPostureRadioimmunoassayBlood PressureBiological effectHypotension OrthostaticInsulin-like growth factorHeart RateInternal medicineHeart rateInternal MedicineHumansMedicineInsulin-Like Growth Factor IHypertensive groupbusiness.industryPlasma levelsBlood pressureEndocrinologyPressure loadHypertensionFemalebusinesshormones hormone substitutes and hormone antagonistsAmerican Journal of Hypertension
researchProduct

Condylar growth after non-surgical advancement in adult subject: a case report.

2007

Abstract Background A defect of condylar morphology can be caused by several sources. Case report A case of altered condylar morphology in adult male with temporomandibular disorders was reported in 30-year-old male patient. Erosion and flattening of the left mandibular condyle were observed by panoramic x-ray. The patient was treated with splint therapy that determined mandibular advancement. Eight months after the therapy, reduction in joint pain and a greater opening of the mouth was observed, although crepitation sounds during mastication were still noticeable. Conclusion During the following months of gnatologic treatment, new bone growth in the left condyle was observed by radiograph,…

AdultMalelcsh:Specialties of internal medicinemedicine.medical_treatmentClinical NeurologyDentistryCase ReportCondylestomatognathic systemlcsh:RC581-951Radiography PanoramicMedicineHumansGeneral DentistryMasticationReduction (orthopedic surgery)OrthodonticsBone growthbusiness.industryDentistry(all)Mandibular CondyleTemporomandibular Joint Disordersstomatognathic diseasesSplintsOtorhinolaryngologySplintsJoint painOral and maxillofacial surgeryNeurology (clinical)medicine.symptombusinessSplint (medicine)Headface medicine
researchProduct

Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives

2000

Previous evidence has demonstrated a relationship between growth factors and cardiovascular diseases. This study was aimed at evaluating levels of some endothelium-derived growth factors, and their relationship with microalbuminuria (MAU), in essential hypertension. Ninety-nine mild-moderate essential hypertensives (EH) and 25 healthy controls were studied. All patients underwent 24-h blood pressure monitoring, serum endothelin-1 (ET-1), basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF), and 24-h MAU assays. Later, EH were divided into two subsets consisting of microalbuminurics (MAU >11 microg/min) and nonmicroalbuminurics (MAU <11 microg/min). In microalbumin…

AdultMalemedicine.hormonemedicine.medical_specialtyPlatelet-derived growth factorBasic fibroblast growth factorBlood PressureEnzyme-Linked Immunosorbent AssayEssential hypertensionEndothelinschemistry.chemical_compoundInternal medicineInternal MedicinemedicineAlbuminuriaHumansPlatelet-Derived Growth FactorCreatinineProteinuriaEndothelin-1business.industryBlood Pressure Monitoring Ambulatorymedicine.diseaseEndocrinologyBlood pressurechemistrySpectrophotometryCreatinineHypertensionFemaleFibroblast Growth Factor 2MicroalbuminuriaEndothelium Vascularmedicine.symptombusinessBiomarkersAmerican Journal of Hypertension
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct